SIRT1 and metabolic dysfunction-associated steatotic liver disease: Both melatonin and SRT 1720 inhibit the development of non-alcoholic fatty liver disease (NAFLD) through indirect or direct activation of SIRT1 (Niu et al., 2018; Stacchiotti et al., 2019).